A Study of IBI362 in Subjects With HFpEF or HFmrEF Combined With Obesity
NCT06862908 on ClinicalTrials.gov · last registry update 2026-09-22
Closed to new participants; the 141 already enrolled are still being followed. Its estimated completion date, 24 September 2026, has passed with no update to the record. Primary outcome, as filed: Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS). A lapsed estimate is not a result and not a failure — sponsors are slow to refile — but ClinicalTrials.gov marks it nowhere on the record, so it is noted here. mazdutide is not approved in the US for anything yet, so this is a drug in development rather than an established treatment being extended. The registry entry has been edited 1 time since then.
- Status
- ACTIVE_NOT_RECRUITING
- Phase
- P2
- Drug
- mazdutide
- Sponsor
- Innovent Biologics (Suzhou) Co. Ltd.
- Sponsor type
- Industry
- Enrollment
- 141
- Started
- 2025-03-26
- Primary completion
- 2026-09-24 estimated
Observed history
Every change this record has made since we started watching it. ClinicalTrials.gov shows only the current value. When a field is edited the previous one is overwritten and nothing is published to say so, so this history exists only because someone was recording it at the time.
| Detected | Change | Detail |
|---|---|---|
| 2026-09-22 | Status changed | RECRUITING → ACTIVE_NOT_RECRUITING |
Primary outcome
Change in Kansas City Cardiomyopathy Questionnaire Clinical Summary Score (KCCQ-CSS)
Conditions studied
Obesity · Heart Failure With Preserved Ejection Fraction (HFPEF) · Heart Failure With Mildly Reduced Ejection Fraction
Every field above is taken directly from the registry record. See all detected changes across the class, or the mazdutide page for this molecule’s full trial and approval history.